Clinical Sciences - Antiviral Smorgasbord

182 - BASELINE CD4 PERCENTAGE IS PREDICTIVE OF SURVIVAL IN PATIENTS STARTING ANTIRETROVIRAL THERAPY, INCLUDING THOSE WITH ABSOLUTE CD4 CELL COUNTS BETWEEN 200 AND 350 CELLS/µL

183 - DISCORDANT IMMUNOLOGIC AND VIROLOGIC RESPONSES TO HAART ARE ASSOCIATED WITH INCREASED MORTALITY AND POOR ADHERENCE TO THERAPY

184 - ELECTIVE TREATMENT INTERRUPTION (ETI) IN VIROLOGICALLY SUPPRESSED HIV-INFECTED ADULTS WITH HIGH CD4 COUNTS

185 - DISCONTINUING OR MODIFYING HAART REGIMENS

186 - IMPROVED HEALTH CARE UTILIZATION AND COST BENEFITS AT MULTIPLE LEVELS WITH OPTIMAL HIV TREATMENT ADHERENCE AND EFFICACY IN AN ELUSIVE AND VULNERABLE INNER CITY POPULATION: RESULTS FROM THE EDMONTON DOT FOR HAART PROJECT

187 - LONG TERM OUTCOME OF DISCONTINUATION OF MAINTENANCE THERAPY FOR CYTOMEGALOVIRUS RETINITIS (CMVR) IN HIV-INFECTED PATIENTS WHO HAVE RESPONDED TO HAART